Endostatin, the 20-kDa C-terminal fragment of collagen XVIII, has previously been shown to inhibit growth and induce regression of different experimental tumors in rodents. In this study, we show that recombinant murine and human endostatin, produced in 293 EBNA cells and yeast, respectively, inhibit ectotopic as well as orthotopic growing BT 4 C n gliosarcomas in BD-IX rats. In rats in which s.c. gliomas were grown for a total of 29 days, systemic treatment with recombinant murine endostatin induced about 50% reduction of intratumoral blood ow and tumor size after only 10 days of therapy. In contrast, the blood ow to irrelevant organs was unaffected by endostatin, indicating its speci city of action. Tumors were not observed to increase in size or regrow after cessation of therapy. Furthermore, endostatin-treated rats with i.c. tumors had signi cantly longer survival time than did untreated controls. In the treated rats, endostatin therapy resulted in a reduced tumor blood vessel volume and an increased tumor cell density with an increased apoptotic index within a given tumor volume, as veri ed by ow cytometry and by staining with deoxynucleotidyltransferase-mediated dUTP nick-end labeling. This work veri es the general anti-angiogenic and antitumor effects of endostatin and indicates that the protein may also be considered as a treatment strategy for malignant brain tumors. Neuro-Oncology 4, 1-8, 2002 (Posted to Neuro-Oncology [serial online], Doc. 01-015, September 27, 2001 T he recruitment of new blood vessels is regarded as essential for continuous tumor growth and metastasis (Folkman, 1990). Recently, several inhibitors of angiogenesis have been identi ed, and much attention has been paid to endostatin, which is a 20-kDa C-terminal proteolytic fragment of collagen XVIII (O'Reilly et al., 1997). This heparin-binding fragment has been shown to inhibit tumor growth in different experimental model systems Chen et al., 1999;Read et al., 2001;Yamaguchi et al., 1999). The exact mechanism of action is still not understood, but the molecule may induce apoptosis of bovine pulmonary endothelial cells (Dhanabal et al., 1999). However, whether this applies to endothelial cells from the tumor vasculature is unknown.Murine endostatin, produced as a recombinant protein in Escherichia coli, has been shown to inhibit tumor growth when administered daily to mice bearing ectopic Lewis lung carcinoma, T241 brosarcoma, or B16F10 melanoma. Importantly, the tumors apparently do not develop resistance to endostatin therapy, but tumor
Neuro-Oncologyregrowth may be observed upon termination of endostatin treatment . However, one study suggests this may be avoided by giving cycled endostatin therapy, which appears to induce a dormant tumor state that persists even after discontinuation of therapy .Most in vivo tumor inhibition experiments with endostatin have been performed in mice with s.c. tumors using precipitated endostatin produced in E. coli and given s.c. in doses of 3 to 20 mg/kg body weight (O'Reilly et al., 1997). Because...